Literature DB >> 6814356

Disposition of arildone, an antiviral agent, after various routes of administration.

D P Benziger, J Edelson.   

Abstract

[14C]arildone was administered both topically and intravaginally to mice 5 times a day for 7 days to simulate conditions of clinical usage. Urinary and fecal excretion of radioactivity indicated that arildone was extensively absorbed by both routes of administration. The levels of radioactivity in the vagina and skin declined from about 12 micrograms equivalents per g to 3 micrograms equivalents per g between 1 and 2 days after the last application. Only small amounts of unchanged arildone were found in urine from the vaginally treated animals; the major urinary metabolites were chloromethoxyphenol, its sulfate ester, and chlorohydroquinone sulfate. After about 1 month of daily oral administration of arildone to rats and monkeys or vaginal administration three times a day for 20 days to dogs, only low levels of intact drug were found in the systemic circulation. The disposition or beta-phase half-life of arildone in monkeys after intravenous administration was about 0.5 h. The disposition of [14C]arildone in mice, rats, dogs, and monkeys after various routes of administration was also investigated.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6814356      PMCID: PMC183768          DOI: 10.1128/AAC.22.3.475

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  Inhibition of uncoating of poliovirus by arildone, a new antiviral drug.

Authors:  J J McSharry; L A Caliguiri; H J Eggers
Journal:  Virology       Date:  1979-09       Impact factor: 3.616

2.  Effect of arildone on modifications of poliovirus in vitro.

Authors:  L A Caliguiri; J J McSharry; G W Lawrence
Journal:  Virology       Date:  1980-08       Impact factor: 3.616

3.  The analysis of arildone in plasma, urine and feces by gas--liquid chromatography with electron-capture detection.

Authors:  G B Park; P Erdtmansky; M P Kullberg; J Edelson
Journal:  J Chromatogr       Date:  1981-02-13

4.  Preliminary studies of the mode of action of arildone, a novel antiviral agent.

Authors:  M F Kuhrt; M J Fancher; V Jasty; F Pancic; P E Came
Journal:  Antimicrob Agents Chemother       Date:  1979-06       Impact factor: 5.191

5.  Metabolism of arildone, an antiviral agent, in laboratory animals.

Authors:  D P Benziger; A K Fritz; S D Clemans; J Edelson
Journal:  Drug Metab Dispos       Date:  1981 Sep-Oct       Impact factor: 3.922

6.  Antiviral activity of arildone on deoxyribonucleic acid and ribonucleic acid viruses.

Authors:  K S Kim; V J Sapienza; R I Carp
Journal:  Antimicrob Agents Chemother       Date:  1980-08       Impact factor: 5.191

7.  Antiviral activity of some beta-diketones. 2. Aryloxy alkyl diketones. In vitro activity against both RNA and DNA viruses.

Authors:  G D Diana; U J Salvador; E S Zalay; P M Carabateas; G L Williams; J C Collins; F Pancic
Journal:  J Med Chem       Date:  1977-06       Impact factor: 7.446

8.  Antiviral activity of some beta-diketones. 1. Aryl alkyl diketones. In vitro activity against both RNA and DNA viruses.

Authors:  G D Diana; U J Salvador; E S Zalay; R E Johnson; J C Collins; D Johnson; W B Hinshaw; R R Lorenz; W H Thielking; F Pancic
Journal:  J Med Chem       Date:  1977-06       Impact factor: 7.446

  8 in total
  3 in total

1.  Metabolism and disposition of amifloxacin in laboratory animals.

Authors:  J A Johnson; D P Benziger
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

2.  In vitro percutaneous absorption of arildone, a highly lipophilic drug, and the apparent no-effect of the penetration enhancer Azone in excised human skin.

Authors:  E J Baker; J Hadgraft
Journal:  Pharm Res       Date:  1995-07       Impact factor: 4.200

Review 3.  Picornavirus inhibitors.

Authors:  L Carrasco
Journal:  Pharmacol Ther       Date:  1994       Impact factor: 12.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.